Table 1.
Patients’ characteristics.
| E-diary (n = 62) | Control (n = 55) | P valuea | |
|---|---|---|---|
| Age | 40.3 ± 11.4 | 42.3 ± 13.9 | 0.38 |
| EDSS | 3.2 ± 2.2 | 2.8 ± 2.0 | 0.34 |
| Disease duration (from diagnosis, years) |
8.2 ± 8.4 | 6.9 ± 8.0 | 0.42 |
| Female | 41 (66%) | 42 (76%) | 0.2 |
| Ethnicity | Jewish: 54 (87%) Arab: 8 (13%) |
Jewish: 37 (67%) Arab: 18 (33%) |
0.1 |
| Active disease at enrolment (relapse or MRI new lesion in previous year) |
20 (32%) | 26 (47%) | 0.1 |
| DMD at baseline | Fingolimod: 25 (40%) Dimethyl fumarate: 18 (29%) Interferon beta: 8 (13%) Teriflunomide: 6 (10%) Glatiramer acetate: 5 (8%) |
Fingolimod: 3 (5%) Dimethyl fumarate: 24 (44%) Interferon beta: 18 (33%) Glatiramer acetate: 10 (18%) |
<0.001 |
EDSS: Expanded Disability Status Scale; DMD: disease-modifying medication.
aP values are from independent group t-test for continuous variables and from chi-square or Fisher’s exact test for categorical variables.